<DOC>
	<DOCNO>NCT02723084</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 8 week treatment combination regimen ABT-493/ABT-530 comparison sofosbuvir plus ribavirin 12 week Hepatitis C Virus Genotype 2 ( GT2 ) infect participant .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ABT-493/ABT-530 Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Screening central laboratory result indicate HCV GT2 infection without coinfection genotype . Subject positive antiHCV Ab plasma HCV RNA viral load great equal 1000 IU/mL Screening Visit . Chronic HCV infection define one following : Positive antiHCV antibody ( Ab ) and/or HCV RNA least 6 month Screening ; A liver biopsy consistent chronic HCV infection . Subject must HCV Directacting antiviral agent ( DAA ) treatmentna√Øve ( i.e. , patient receive single dose approve investigational DAA ) . Prior HCV treatment use IFNs without ribavirin acceptable . Previous HCV Interferon ( IFN ) base treatment must complete great equal 2 month prior screen . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . Positive test result Screening hepatitis B surface antigen ( HBsAg ) anti human immunodeficiency virus antibody ( HIV Ab ) . Requirement inability safely discontinue contraindicate medication supplement least 2 week 10 halflives ( whichever longer ) prior first dose study drug . Clinically significant abnormality , HCVinfection , base upon result medical history , physical examination , vital sign , laboratory profile , 12lead electrocardiogram ( ECG ) make subject unsuitable candidate study opinion investigator , include , limited : Uncontrolled diabetes define glycated hemoglobin ( hemoglobin A1C ) level &gt; 8.5 % Screening Visit . Active suspect malignancy history malignancy ( basal cell skin cancer cervical carcinoma situ ) past 5 year , history HCC . Uncontrolled cardiac , respiratory , gastrointestinal , hematologic , neurologic , psychiatric , medical disease disorder , unrelated exist HCV infection . Any cause liver disease chronic HCVinfection , include limited following : Hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's disease , autoimmune hepatitis , alcoholic liver disease , steatohepatitis consider primary cause liver disease rather concomitant/incidental HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Non-cirrhotic</keyword>
	<keyword>Hepatitis C Genotype 2</keyword>
	<keyword>Chronic Hepatitis C Virus</keyword>
</DOC>